Stock Analiz

X4 Pharmaceuticals, Inc XFOR

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2017 · data as of November 13, 2026

$3.12Market cap $319M
Open the interactive analysis →

X4 Pharmaceuticals, Inc (XFOR) is a healthcare company listed in the US with a market value of about $319M. In the twelve months to September 30, 2026 it had revenue of $17M and net income of -$81M, a net margin of -474.7%.

Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is future growth (3/5); the weakest is shareholder returns (0/5).

Key numbers: a P/E of 5.7, 5-year revenue growth of 64% a year, a 5-year average ROIC of -52%.

About X4 Pharmaceuticals

X4 Pharmaceuticals is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2017. Revenue went from $3M in 2020 to $35M in 2025, growth of about 63.6% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 1897% over three years (dilution for shareholders). It spends 207% of revenue on research and development.

Score: 1.6 / 5

Value2/5
Future growth3/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%
  • Profitable 5 years in a row

Valuation

P/E (TTM)5.7
Forward P/E—
P/FCF—
P/S18.8
P/B2.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-25.5%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)1250.5%
Revenue growth (5 yrs, per year)63.6%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-833.0%
ROIC (5-yr avg.)-51.7%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$17M$35M$3M$0$0$0$3M$0$0——
Net income-$81M-$79M-$37M-$101M-$94M-$89M-$62M-$53M-$33M-$22M-$23M
Free cash flow-$81M-$86M-$131M-$97M-$77M-$72M-$60M-$48M-$25M-$22M-$22M
EPS (diluted)$0.55$-1.87$-5.59$-17.07$-45.60$-119.70$-92.70$-138.90$-2374.50$-1637.40$-41885.78
Net margin-474.7%-225.6%-1440.4%———-2071.0%————
ROIC—-26.2%-28.8%-77.3%-61.5%-64.5%-42.5%-34.0%———

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 5 analysts is $11.60, 272% above the current price; targets range from $10.00 to $13.00; the consensus rating is “Strong buy”; expected EPS is $-0.64 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is X4 Pharmaceuticals’s P/E ratio?

About 5.7, based on the last twelve months of diluted earnings per share.

Does X4 Pharmaceuticals pay a dividend?

Not currently.

Is X4 Pharmaceuticals a good stock to buy?

We do not give buy or sell advice. X4 Pharmaceuticals scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.